PamGene Platform Adopted for Kinase Drug R&D Program
Collaboration with Johnson & Johnson Pharmaceutical Research & Development
PamGene International BV and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica NV have announced significant progress in their kinase profiling collaboration. After extensive evaluation, PamGene's microarray-based biochemical kinase activity profiling and cellular inhibition assays will be further implemented in J&JPRD's research programs.
The evaluation program involved kinase inhibitor characterization on a panel of recombinant kinases. Additionally, a number of reference and J&JPRD proprietary kinase inhibitors were characterized in whole cell-based experiments. Kinase activity was measured by phosphorylation profiles (fingerprints) obtained from the kinetic readout from lysates of compound-treated cells.
Most read news
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.